Keryx drug improves phosphorus, iron in kidney patients: trial

Whatsapp News

A pivotal trial Keryx Biopharmaceuticals Inc’s experimental drug Zerenex showed levels serum phosphorus and iron patients kidney dialysis, according to published .

The trial involved 441 patients, according to the Journal the American Society Nephrology, which published the .

the four-week efficacy assessment period, mean serum phosphorus for Zerenex patients dropped by 2.2 milligrams per deciliter compared with placebo patients, the trial showed.

Most patients with kidney disease requires dialysis need chronic with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels.


The found , if approved, Zerenex would be the only phosphate binder also increases iron stores, reducing the need for other drugs to treat anemia.

Side effects experienced by patients treated with Zerenex included diarrhea, nausea, vomiting and constipation. Serious adverse events were reported 39.1 percent of the Zerenex patients and 49 percent of patients the control group.

The U.S. Food and Drug Administration, which earlier this year cited manufacturing information as the reason for a three-month extension of its of Zerenex, is expected to decide by Sept. 7 whether to approve the drug. (Reuters)